On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
Kohler said the same CAR-T cell therapies have been used for more than a decade. "When you look back, it's easy to see how revolutionary CAR-T cells have been. But, for many patients this therapy ...
CAR T cell therapy against CD19 and B cell maturation antigen (BCMA) is a potent immunotherapy for treating advanced B cell malignancies. It comes with a unique toxicity profile that includes cytokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback